Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2005 4
2007 9
2008 2
2009 9
2010 10
2011 13
2012 21
2013 30
2014 28
2015 47
2016 47
2017 33
2018 51
2019 40
2020 37
2021 37
2022 44
2023 41
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

469 results

Results by year

Filters applied: . Clear all
Page 1
Chiral-Molecule-Based Spintronic Devices.
Shang Z, Liu T, Yang Q, Cui S, Xu K, Zhang Y, Deng J, Zhai T, Wang X. Shang Z, et al. Among authors: xu k. Small. 2022 Aug;18(32):e2203015. doi: 10.1002/smll.202203015. Epub 2022 Jul 14. Small. 2022. PMID: 35836101 Review.
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, Jin L, Xia J, Ma S, Liu Y, Li H, Pan B, Chen W, Fei X, Wang C, Xie X, Yu L, Wang G, Li H, Jing G, Cheng H, Zhu F, Sun H, Sang W, Li D, Li Z, Zheng J, Xu K. Wang Y, et al. Among authors: xu k. J Clin Oncol. 2022 Jul 10;40(20):2246-2256. doi: 10.1200/JCO.21.01676. Epub 2022 Mar 25. J Clin Oncol. 2022. PMID: 35333600 Clinical Trial.
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, Shi M, Tan J, Zhang M, Xiao X, Xia J, Ma S, Qiao J, Yan Z, Li H, Pan B, Sang W, Li D, Li Z, Zhou J, Huang H, Liang A, Zheng J, Xu K. Qi Y, et al. Among authors: xu k. Blood. 2022 Jun 9;139(23):3376-3386. doi: 10.1182/blood.2021013733. Blood. 2022. PMID: 35338773 Free PMC article. Clinical Trial.
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, Cao J, Li D, Cheng H, Sang W, Zhu F, Sun H, Chen W, Qi K, Yan D, Qiu T, Qiao J, Yao R, Liu Y, Wang X, Zhang Y, Peng S, Huang CH, Zheng J, Li Z, Chang AH, Xu K. Xia J, et al. Among authors: xu k. J Clin Oncol. 2023 May 10;41(14):2583-2593. doi: 10.1200/JCO.22.01824. Epub 2023 Mar 7. J Clin Oncol. 2023. PMID: 36881785 Free PMC article. Clinical Trial.
Biomarkers as targets for CAR-T/NK cell therapy in AML.
Shao R, Li Z, Xin H, Jiang S, Zhu Y, Liu J, Huang R, Xu K, Shi X. Shao R, et al. Among authors: xu k. Biomark Res. 2023 Jun 17;11(1):65. doi: 10.1186/s40364-023-00501-9. Biomark Res. 2023. PMID: 37330575 Free PMC article. Review.
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity.
Cui Y, Yuan T, Wang Y, Zheng D, Qin L, Li S, Jiang Z, Lin S, Guo W, Wang Z, Liang Z, Li Y, Yao Y, Liu X, Tang Q, Tu HY, Zhang XC, Tang Z, Wong N, Zhang Z, Qin D, Thiery JP, Xu K, Li P. Cui Y, et al. Among authors: xu k. Cell Rep. 2023 Jul 25;42(7):112797. doi: 10.1016/j.celrep.2023.112797. Epub 2023 Jul 11. Cell Rep. 2023. PMID: 37436890 Free article.
Notch1 regulates hepatic thrombopoietin production.
Sun Y, Tong H, Chu X, Li Y, Zhang J, Ding Y, Zhang S, Gui X, Chen C, Xu M, Li Z, Gardiner EE, Andrews RK, Zeng L, Xu K, Qiao J. Sun Y, et al. Among authors: xu k. Blood. 2024 Apr 11:blood.2023023559. doi: 10.1182/blood.2023023559. Online ahead of print. Blood. 2024. PMID: 38603632
469 results